Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards INDRead More
Yemi has over 20 years of experience in drug manufacturing and cell line development. Prior to working at Selexis, Yemi was director of commercial development at Diosynth RTP Inc. and associate director of business development at Lonza Custom Manufacturing – organizations that provide process development and cGMP manufacturing services in mammalian production platforms. More recently, Yemi was head of sales and marketing at Bachem Americas Inc. - a contract manufacturing organization that focuses on peptides and complex organic molecules. In these positions, he has had a strong record of consistently growing the customer base and sales and expanding product offerings into new markets. Yemi is a member of the board of directors of VLP Biotech Inc, a vaccine development company that is based in San Diego, CA and has been a business advisor to several biopharmaceutical and drug delivery companies. Educated in the UK, Yemi holds a PhD from the University of Kent at Canterbury and an MBA from Imperial College Management School.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2021 Selexis SA. All Rights Reserved.